Join to view full profile
400 Market StreetMontvale, NJ 07645
Phone+1 201-689-3933
Dr. Shtilbans is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Alexander Shtilbans is a neurologist based in Montvale, NJ, specializing in movement disorders with a focus on conditions such as Parkinson's disease. He completed his medical education at the Icahn School of Medicine at Mount Sinai, including an internship in internal medicine and a neurology residency, followed by further study at Columbia University. His expertise includes botulinum toxin injections for movement disorders. Dr. Shtilbans has authored several publications on Parkinson's disease, with notable work published in journals such as Frontiers in Neuroscience and Journal of Neuroimaging. His research has been cited by other publications multiple times. He has also been involved in clinical trials relating to iron accumulation in Parkinson's disease and has received certification honors from Epic Systems Corporation.
Education & Training
Columbia University Vagelos College of Physicians and Surgeons2010 - 2011
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Neurology, 2007 - 2010- Icahn School of Medicine at Mount Sinai/Morningside/WestInternship, Internal Medicine, 2006 - 2007
- Icahn School of Medicine at Mount SinaiClass of 2006
Certifications & Licensure
NJ State Medical License 2017 - 2027
NY State Medical License 2007 - 2027
American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2017
Clinical Trials
- Quantitative Mapping of Substantia Nigra Iron in Parkinson's Disease (Stages I-IV, REM Sleep Behavior Disorder) and Controls Start of enrollment: 2018 Aug 14
Publications & Presentations
PubMed
- QSM vs dopamine transporter PET: χ+ Mapping Shows Stronger Longitudinal Associations with Nigral Degeneration than Conventional QSM in Parkinson's Disease.Chao Zhang, Mert Sisman, Qihao Zhang, Carly Skudin, Alexandra G Roberts
AJNR. American Journal of Neuroradiology. 2026-06-10 - 1 citationsCombination Disease-Modifying Therapy for Neurodegenerative Diseases Using Repurposed Drugs.Alexander Shtilbans, Anthony E Lang
Annals of Neurology. 2026-05-01 - 6 citationsEvaluation of Additive Neuroprotective Effect of Combination Therapy for Parkinson's Disease Using In Vitro Models.Alexander Shtilbans, Elise Esneault, Florian Simon, Joseph R Mazzulli, Drew J Quiriconi
Antioxidants. 2025-03-27
Journal Articles
- Clinical Quantitative Susceptibility Mapping (QSM): Biometal Imaging and Its Emerging Roles in Patient CareGary M Brittenham, Apostolos John Tsiouris, Lawrence Tanenbaum, Ajay Gupta, Martin R Prince, Jonathan W Weinsaft, Susan A Gauthier, Brian H Kopell, Michael G Kaplitt, ..., Journal of Magnetic Resonance Imaging
Press Mentions
Innovative Study Identifying Early Biomarkers for Parkinson's Disease Receives FundingMarch 4th, 2025- He Suddenly Shuffled When He Walked. Why?April 9th, 2026
Professional Memberships
- Member
- Movement Disorder SocietyMember
- Member
Other Languages
- Russian
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
